NEW YORK (GenomeWeb News) – Geneart said yesterday that the European Commission has awarded it€300,000 ($470,000) under its 7th Framework Program to participate in a project called "New HIV Vaccines Inducing Broadly Reactive Neutralizing Antibodies."
The Regensburg, Germany-based firm will create custom-designed gene sequences for HIV vaccine candidates being developed by the project, which is coordinated by Sanofi Pasteur, the vaccines division of Sanofi-Aventis. The consortium behind the project includes 15 research groups that have received a total contribution of nearly €12 million from the European Union.
Geneart said that its technology would be used to optimize gene sequences for highest yields in the selected production system. In addition, it said it would “systemically analyze the influence of different sequence motives — specific successions of bases in a given gene — on production rates in the laboratory.”